Report Overview

The US Non-Small Cell Lung Cancer (NSCLC) market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and accounted for around 85% of all lung cancers in the United States. Increasing use of biomarker testing, increasing incidence of NSCLC cases, increase in the mutation of specific trials activity and approval drive the growth of the market



Market Drivers

Rising prevalence of NSCLC across the US due to increasing air pollution and smoking habits amongst the people is likely to drive the market over the coming years. The American Cancer Society estimates that about 224,390 new lung cancer patients will be diagnosed in 2016 in the US. The presence of a strong pipeline and research activities undertaken by various industry players and academic institutions also drives the market growth. In 2015, The U.S food and Drug Administration approved Pembrolizumab for the first time as a viable treatment alternative for the Non-small cell lung cancer patients who have high PD-L1 expression and have failed to respond to the other treatment modalities. In 2017, the FDA granted accelerated approval for Pembrolizumab to be used as a first line combination alternative for Non-Squamous NSCLC irrespective of the PD-L prognosis. Thus, all of these factors are expected to bolster the market growth substantially over the forecast period